strong tavr bolster case ew
signific us ww tavr drive ep upsid
investor sentiment brace miss us tavr grew
upper teen ou tavr grew mid-teen repres signific
acceler driven part increas awar benefit
tavr due impress low-risk tavr clinic trial data present
march management cite rang factor contribut strength
includ increas awar improv effici move patient
referr treatment process also suspect lower stroke
rate vs patient receiv tavr vs surgeri
like also make easier choos tavr savr
reiter outperform rate ew rais tp
guidanc help prevent street get ahead
impress tavr growth sequenti acceler
encourag mgmt specif top-lin guidanc given
histori street get ahead management deliv
histor compani weakest season quarter
ew go substanti upsid base
valuat analysi publish price holt
analysi publish see valuat support tp
exampl sensit analysi suggest stock price impli
market-impli long-term sale growth
valuat target price base
ev/ebitda multipl unch bil ebitda estim
regulatory/qu issu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
global manufactur provid
medic devic equip structur valvular heart
diseas critic care
price jul rate outperform target price analyst matt miksic
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
one-year valuat scenario base
ev/ebitda ebitda
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
one-year valuat grey scenario base
ev/ebitda grey ebitda grey
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
addit detail takeaway
tavr mil mil y/i underli vs cse
compani estim grew in-lin ww tavr growth remain
stabl compani continu exercis price disciplin compani
estim ww tavr procedur grew mid-teen ew tavr sale
high-teen growth driven increas confid
clinic trial data patient continu treat low-risk continu
access protocol cap high-volum clinic trial site manag
estim fda approv sapien sapien ultra low-risk
indic manag estim share procedur stabl growth
broad-bas across high- low-volum center ou tavr procedur grew
mid-teen ew growth compar europ tavr procedur also grew
mid-teen ew growth compar launch sapien ultra
on-going eu compani expect sapien ultra account major
tavr sale europ year-end japan manag continu see strong tavr
adopt driven sapien final manag made strateg decis
discontinu centera platform given extens cost invest
platform clinic success sapien platform ew enrol patient
 pivot trial studi centera valv intermedi risk patient compani
expect underli tavr sale bil bil previous
tmtt mitral tricuspid program continu progress
tmtt sale mil driven continu roll-out pascal eu compani
remain focus physician train compani also continu treat patient
commerci cardioband given improv suppli follow transfer
product cardioband ew manufactur facil compani
continu enrol patient clasp pivot trial studi pascal patient
primari degen mitral valv diseas data one-year clasp studi
expect present tct meet septemb addit compani
receiv approv enrol patient clasp pivot trial patient
function mitral diseas plan initi enrol late mitral
replac compani enrol patient earli feasibl studi
evoqu also enrol patient earli feasibl studi sapien
plan initi pivot trial late tricuspid repair compani expect
initi tricuspid pivot trial use pascal late also expect initi
second tricuspid pivot trial cardioband sometim futur
compani expect tmtt sale mil estim ww tmtt opportun
reach bil
surgic structur heart mil mil y/i cc vs
solid underli growth driven continu adopt newer premium aortic valv
ou strength partial off-set lower surgic aortic heart valv procedur
 tavr adopt expand compani also continu launch inspiri
resilia aortic valv major region quarter indic notabl usag
activ patient might otherwis get mechan valv manag expect
harpoon system commerci avail europ late compar
previou expect launch result slow regulatori environ
europ compani expect sale mil
critic mil mil y/i cc vs cse
sale y/i exclud casm acquisit underli ex-
casm integr casm mil sale underway compani expect
sale top end mil rang
compani increas sale guidanc bil bil
equat underli growth manag expect underli sale growth
top end rang ep guidanc also rais
fx expect neg impact sale mil
compani expect sale bill ep
 op margin bp estim
bottom line sale net cog lower non-op partial off-set
higher sg higher deliv ep estim
gross margin bp y/i driven favor fx product mix
partial off-set invest global suppli chain expans
sale
sale
estimate
ep
sale
sale
estimate
chang model
increas sale estim ep estim
also made rel minor adjust top-lin project
beyond increas sale estim per year averag year ep
figur chang model
charl martineau pm univers toronto compani mention price
